Jang-yang Z. Chang
Taipei, TNQ 11031, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications
BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Journal: Science translational medicine
Published: February 18, 2026
Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.
Journal: Cancer immunology, immunotherapy : CII
Published: June 07, 2025
EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis.
Journal: Neoplasia (New York, N.Y.)
Published: February 25, 2025
Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer.
Journal: Journal of biomedical science
Published: February 19, 2025
Upregulation of Cathepsin S Expression Contributes to Neuronal Damage Following Kainic Acid-Induced Status Epilepticus.
Journal: Journal of neurochemistry
Published: December 17, 2024
Oral Cancer-Derived miR-762 Suppresses T-Cell Infiltration and Activation by Horizontal Inhibition of CXCR3 Expression.
Journal: International journal of molecular sciences
Published: November 11, 2024
The miR-876-5p/SOCS4/STAT3 pathway induced the expression of PD-L1 and suppressed antitumor immune responses.
Journal: Cancer cell international
Published: August 30, 2024
Tumor cell-derived ISG15 promotes fibroblast recruitment in oral squamous cell carcinoma via CD11a-dependent glycolytic reprogramming.
Journal: Oncogenesis
Published: August 06, 2024
Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models.
Journal: Pharmacological research
Published: June 17, 2024
Targeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function.
Journal: Journal of biomedical science
Published: November 27, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: Targeted oncology
Published: August 31, 2023
Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death.
Journal: Pharmacological research
Published: June 15, 2023
Last Updated: 09/26/2026